The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The initiative aims to connect startups and tech companies with its business units,
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Facility designed to advance the next generation of imaging systems
Subscribe To Our Newsletter & Stay Updated
